StreetAlpha.app
Home › Stocks › HUMA

Humacyte, Inc. (HUMA)

Healthcare
$0.50
▼ −7.27%
LAST CLOSE · NOV 17

Humacyte makes bioengineered human blood vessels, sold as Symvess, for hospitals and trauma centers. It last closed at $0.50 on Nov 17, down 7.27% on the day.

AI Auto Pilots
Is HUMA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$2.4M
+52.5% vs a year ago
Net income
−$94.8M
−3955.1% margin
EPS (diluted)
−$0.45
Free cash flow
−$88.6M
−3697.0% margin
Valuation
Market cap
$139.2M
277.8M shares
P/E
–
No P/E while losing money
Price to sales
58.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$64.5M
At Sep 30
Debt
$36.8M
At Sep 30
Shareholder equity
$18.1M
Shares outstanding
277.8M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $2.0M$2.0MFY2025

From HUMA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Hold
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Hold
1firm
0 Buy1 Hold0 Sell
Only 1 firm rated HUMA in the past 90 days, not enough for a consensus
Average 12-month target
$0.60
▲ 19.8% upside

Based on 1 analyst who set a price target on HUMA in the past 90 days. The average target is $0.60, with a high of $0.60 and a low of $0.60, compared with the last close of $0.50.

Low $0.60Avg $0.60High $0.60
Blue marker: last close $0.50
Highest target$0.60
Average target$0.60
Lowest target$0.60
Latest rating changes
BarclaysTarget raised
Nov 11Hold$0.50 → $0.60
BarclaysInitiated
Oct 7Hold$0.50
TD CowenMaintained
Jun 17Buy$1.25
HC Wainwright & Co.Target raised
Jun 11Buy$3 → $4
BTIGReiterated
Jun 8Buy$2
DateFirmActionRatingPrice target
Nov 11BarclaysTarget raisedHold$0.50 → $0.60
Oct 7BarclaysInitiatedHold$0.50
Jun 17TD CowenMaintainedBuy$1.25
Jun 11HC Wainwright & Co.Target raisedBuy$3 → $4
Jun 8BTIGReiteratedBuy$2
Loading…

Technical Analysis

HUMA · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock is 6% above its 20 day and 2% above its 50 day average. It is 55% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 51). The nearest support is the 50 day average at $0.49, and the nearest resistance the swing high (Oct 29) at $0.51.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 11.6%/day
Key levels
$1.5352 week high+206.0%
$0.77200 day average+54.0%
$0.58100 day average+16.0%
$0.55Pivot R1+10.0%
$0.53Pivot+6.0%
$0.51Swing high (Oct 29)+2.0%
$0.50Last close
$0.4950 day average−2.0%
$0.48Pivot S1−4.0%
$0.4720 day average−6.0%
$0.39Swing low (Oct 26)−22.0%
$0.3452 week low−32.0%
Indicators
RSI (14)51.47Middle of its rangeNeutral
MACD0.02Above its signal lineBullish
Stochastic60.5Middle of its rangeNeutral
ADX (14)22.7Weak trend
Williams %R-52.6Oversold below −80, overbought above −20Neutral
CCI (20)63.6Oversold below −100, overbought above 100Neutral
Rate of change+13.7%Change over 10 sessionsBullish
ATR (14)$0.06Typical daily range, 11.6% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for HUMA

What happened before

See how HUMA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow HUMA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How HUMA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in HUMA in the last 90 days.

Loading…

See today’s whale options flow across the market →

HUMA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼50 buying vs 86 selling
  • ▼Held by funds -6.8 pts
  • ▼Funds holding -34
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding129163−20.9%
In funds' top 1000–
Held by funds19.6%26.4%−6.8 pts
New / increased12 / 3838 / 57−47.4%
Reduced / sold out40 / 4636 / 33+24.6%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See HUMA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HUMA is in one of them and how their past HUMA trades turned out.

HUMA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered HUMA in an article yet. Here's the latest on the wider market.

HUMA Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jun 14
Who traded HUMA · since 2022
Latest 5 filings of 15
$1K – $15KTraded May 3, 2024Filed Jun 14, 2024
$1K – $15KTraded May 3, 2024Filed Jun 14, 2024
$15K – $50KTraded May 3, 2024Filed Jun 14, 2024
$15K – $50KTraded May 3, 2024Filed Jun 14, 2024
Tommy TubervilleSell (partial)
$50K – $100KTraded Apr 30, 2024Filed May 15, 2024
PersonTypeAmountTradedFiledDelay
Tommy TubervilleR · ALSell$1K – $15KMay 3, 2024Jun 14, 202442 d
Tommy TubervilleR · ALSell$1K – $15KMay 3, 2024Jun 14, 202442 d
Tommy TubervilleR · ALSell$15K – $50KMay 3, 2024Jun 14, 202442 d
Tommy TubervilleR · ALSell$15K – $50KMay 3, 2024Jun 14, 202442 d
Tommy TubervilleR · ALSell (partial)$50K – $100KApr 30, 2024May 15, 202415 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Humacyte

Humacyte is a biotechnology company based in Durham, North Carolina, that makes bioengineered human tissues for surgical repair and replacement. Its main product is an acellular tissue engineered vessel sold under the name Symvess, which is approved in the United States as a vascular conduit for adults with arterial injury to the limbs. The company is developing additional vessels for uses such as dialysis access and peripheral artery disease. Its vessels are shipped to hospitals, trauma centers and outpatient surgical settings.

Headquarters
Durham, NC